#### Engineering Conferences International ECI Digital Archives

Integrated Continuous Biomanufacturing III

Proceedings

9-17-2017

### Development and application of screening scale bioreactor systems for very high cell density perfusion of mammalian cells

Caijuan Zhan KTH - Cell Technology Group (CETEG), Sweden

Hubert Schwarz *KTH - Cell Technology Group (CETEG), Sweden* 

Magnus Lundqvist *KTH - Cell Technology Group (CETEG), Sweden* 

Atefeh Shokri KTH - Cell Technology Group (CETEG), Sweden

Ray Field BioPharmaceutical Development, MedImmune, Cambridge, UK.

See next page for additional authors

Follow this and additional works at: http://dc.engconfintl.org/biomanufact\_iii Part of the <u>Engineering Commons</u>

#### **Recommended** Citation

Caijuan Zhan, Hubert Schwarz, Magnus Lundqvist, Atefeh Shokri, Ray Field, Richard Turner, Mathias Uhlén, Johan Rockberg, and Veronique Chotteau, "Development and application of screening scale bioreactor systems for very high cell density perfusion of mammalian cells" in "Integrated Continuous Biomanufacturing III", Suzanne Farid, University College London, United Kingdom Chetan Goudar, Amgen, USA Paula Alves, IBET, Portugal Veena Warikoo, Axcella Health, Inc., USA Eds, ECI Symposium Series, (2017). http://dc.engconfintl.org/biomanufact\_iii/52

This Abstract and Presentation is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Integrated Continuous Biomanufacturing III by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.

#### Authors

Caijuan Zhan, Hubert Schwarz, Magnus Lundqvist, Atefeh Shokri, Ray Field, Richard Turner, Mathias Uhlén, Johan Rockberg, and Veronique Chotteau







# **Development and application of screening scale bioreactor systems for** very high cell density perfusion of mammalian cells

<u>Caijuan Zhan<sup>1,4</sup>, Hubert Schwarz<sup>1,4</sup>, Ye Zhang<sup>1,4</sup>, Atefeh Shokri<sup>1,4,6</sup>, Ray Field<sup>3</sup>, Richard Turner<sup>3</sup>,</u> Johan Rockberg<sup>2,4,5</sup>, Veronique Chotteau<sup>1,4,6</sup>

<sup>1</sup> KTH - Cell Technology Group (CETEG), Div. of Industrial Biotechnology, School of Biotechnology, SE-10691, Stockholm, Sweden <sup>2</sup> KTH - Royal Institute of Technology, Dept. Proteomics & Nanobiotechnology, SE-10691 Stockholm, Sweden <sup>3</sup> BioPharmaceutical Development, MedImmune, Cambridge, UK <sup>4</sup> Wallenberg Centre for Protein Research (WCPR) <sup>5</sup> NovoNordisk Center for Biosustainability (NNF CFB)

Processing

<sup>6</sup> AdBIOPRO, Competence Centre for Advanced Bioproduction by Continuous



## **Acknowledgements**

This work was supported by the Knut and Alice Wallenberg Foundation, Sweden, and by MedImmune, AstraZeneca, UK. We thank Thermo Fisher Scientific, USA, for kindly providing PM8 prototype medium and Irvine Scientific, USA, for advices, as well as Selexis/JSR, Switzerland, for the CHO-M cell line.